Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Appl Radiat Isot ; 204: 111121, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38016259

RESUMO

SPES (Selective Production of Exotic Species) is a second generation facility for the production of radioactive ion beams that is going to be commissioned at the Laboratori Nazionali di Legnaro of INFN at Legnaro, Padua, Italy. Radioactive neutron-rich isotopes are expected to be produced by nuclear fission induced by a 40 MeV, 200 µA primary proton beam impinging on a 238UCx target. The expected reaction rate is about 1013 fission/s. Radioactive ion beams are produced using the isotope separation on-line technique. The production of such an amount of radioactive species raises radiological issues throughout the life cycle of the facility. A study of the radioactive contamination of the components of the radioactive ion beam line is performed with the FLUKA Monte Carlo simulation code, under realistic hypotheses for the produced isobaric beams. The present results complete previous studies focused on the radiological impact of the production target irradiation, the residual activation of the primary proton beam line and the radioactive contamination of the ion source complex. The overall ambient dose equivalent rate due to the different radiation sources is calculated at several positions inside the production bunker and at different times after a typical one-year operating period of the facility with the 238UCx target at full power. The obtained results and the developed methodology provide the guidelines and the needed tools to plan ordinary and extraordinary interventions as well as final decommissioning of the SPES facility.

2.
Appl Radiat Isot ; 197: 110798, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-37028101

RESUMO

Radio Pharmaceutical Therapy (RPT) comes forth as a promising technique to treat a wide range of tumors while ensuring low collateral damage to nearby healthy tissues. This kind of cancer therapy exploits the radiation following the decay of a specific radionuclide to deliver a lethal dose to tumor tissues. In the framework of the ISOLPHARM project of INFN, 111Ag was recently proposed as a promising core of a therapeutic radiopharmaceutical. In this paper, the production of 111Ag via neutron activation of 110Pd-enriched samples inside a TRIGA Mark II nuclear research reactor is studied. The radioisotope production is modeled using two different Monte Carlo codes (MCNPX and PHITS) and a stand-alone inventory calculation code FISPACT-II, with different cross section data libraries. The whole process is simulated starting from an MCNP6-based reactor model producing the neutron spectrum and flux in the selected irradiation facility. Moreover, a cost-effective, robust and easy-to-use spectroscopic system, based on a Lanthanum Bromo-Chloride (LBC) inorganic scintillator, is designed and characterized, with the aim of using it, in the future, for the quality control of the ISOLPHARM irradiated targets at the SPES facility of the Legnaro National Laboratories of INFN. natPd and 110Pd-enriched samples are irradiated in the reactor main irradiation facility and spectroscopically characterized using the LBC-based setup and a multiple-fit analysis procedure. Experimental results are compared with theoretical predictions of the developed models, showing that inaccuracies in the available cross section libraries prevent an accurate reproduction of the generated radioisotope activities. Nevertheless, models are normalized to our experimental data allowing for a reliable planning of the 111Ag production in a TRIGA Mark II reactor.


Assuntos
Radioisótopos , Compostos Radiofarmacêuticos , Relação Dose-Resposta à Radiação , Compostos Radiofarmacêuticos/uso terapêutico , Reatores Nucleares
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA